Pharma Bavaria International GmbH

pharma-bavaria.com

Pharma Bavaria International is a global reach company that distributes and promotes high-quality pharmaceuticals with well-researched ingredients. In line with our vision - Access to Quality Healthcare - we offer a vast portfolio of prescription’s medicines that includes different therapeutic options for different pathologies, plus Pharma Bavaria International has LAB BOTANIC BAVARIA, an umbrella that covers OTCs and a range of herbal/supplement products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

news image

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More

BUSINESS INSIGHTS

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

news image

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

INSITRO APPOINTS PHILIP TAGARI, INDUSTRY-LEADING SCIENTIST AND DRUG HUNTER, AS CHIEF SCIENTIFIC OFFICER

insitro | December 02, 2022

news image

insitro, a machine learning-powered drug discovery and development company announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery. “I am deeply excited to partner with Philip on insitro’s journey to build a transformative biology platform for...

Read More

BUSINESS INSIGHTS

AQEMIA ANNOUNCES AN EXTENSION OF ITS FIRST COLLABORATION WITH SANOFI ABOUT AI AND QUANTUM PHYSICS-DRIVEN DRUG DISCOVERY IN ONCOLOGY

Aqemia | June 16, 2022

news image

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi. This new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi. This initial collaboration resulted...

Read More
news image

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More
news image

BUSINESS INSIGHTS

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More
news image

BUSINESS INSIGHTS, PHARMACY MARKET

INSITRO APPOINTS PHILIP TAGARI, INDUSTRY-LEADING SCIENTIST AND DRUG HUNTER, AS CHIEF SCIENTIFIC OFFICER

insitro | December 02, 2022

insitro, a machine learning-powered drug discovery and development company announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery. “I am deeply excited to partner with Philip on insitro’s journey to build a transformative biology platform for...

Read More
news image

BUSINESS INSIGHTS

AQEMIA ANNOUNCES AN EXTENSION OF ITS FIRST COLLABORATION WITH SANOFI ABOUT AI AND QUANTUM PHYSICS-DRIVEN DRUG DISCOVERY IN ONCOLOGY

Aqemia | June 16, 2022

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi. This new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi. This initial collaboration resulted...

Read More